NASDAQ:EXEL 17 August 2025

Exelixis Up After Merck Pact Focuses Attention on Cancer Study
·····

Exelixis Up After Merck Pact Focuses Attention on Cancer Study

Exelixis shares climbed Wednesday after the company announced a new Merck partnership, putting its next cancer drug program further into late-stage trials. Shares traded 2.5% higher at $49.89 in the afternoon, putting the Alameda, California-based company’s market cap near $13.3 billion. Biotech stocks were strong, with the iShares Nasdaq Biotechnology ETF up 1.8% and the SPDR S&P Biotech ETF up 3.8%.
May 20, 2026
Senolytic Drugs
··········

The Secret “Zombie Cell” Killers: Niche Senolytic Drugs Fighting Aging’s Clock

For centuries, people have searched for a fountain of youth. Today, scientists are zeroing in on an intriguing strategy – senolytic drugs – that might help turn back the biological clock. These compounds target the so-called “zombie cells” in our bodies, officially known as senescent cells, which stop dividing but refuse to die nature.com. As we age, these senescent cells accumulate and spew out harmful signals that drive inflammation, tissue damage, and aging itself nature.com. Senolytics are designed to selectively destroy these damaged cells, potentially slowing aging and alleviating many age-related conditions with a single treatment. Researchers discovered the first senolytic breakthrough in 2015, when a Mayo Clinic and Scripps Research team found that a combination of two compounds –
August 17, 2025